IGC Pharma (IGC) Return on Capital Employed (2011 - 2025)
IGC Pharma (IGC) reported Return on Capital Employed of 110.45% for Q3 2025, down 8107.0% year-over-year from 1.38% in Q3 2024, and down 5.12% quarter-over-quarter from 105.08% in Q2 2025.
IGC Pharma (IGC) Return on Capital Employed (2011 - 2025) Analysis & Trends
IGC Pharma (IGC) has 15 years of Return on Capital Employed data on file, last reported at 110.45% in Q3 2025.
- Return on Capital Employed for Q3 2025 came in at 110.45%, down 8107.0% year-over-year; the trailing twelve-month figure through Sep 2025 was 110.45% (down 8107.0% YoY), and the FY2026 annual result was 40.34%, down 1919.0% from the prior year.
- Return on Capital Employed slipped to 110.45% in Q3 2025 per IGC's latest filing, from 105.08% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 6.39% in Q2 2021 and troughed at 111.89% in Q1 2025.
- A 5-year average of 31.29% and a median of 15.48% in 2021 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2022 and 2025: Return on Capital Employed surged 636 bps in 2022, then tumbled 8107 bps in 2025.
- A 5-year view of Return on Capital Employed shows it stood at 15.48% in 2021, then soared by 41 bps to 9.13% in 2022, then sank by 130 bps to 21.03% in 2023, then advanced by 24 bps to 16.08% in 2024, then tumbled by 587 bps to 110.45% in 2025.
- Business Quant data shows IGC's Return on Capital Employed at 110.45% in Q3 2025, 105.08% in Q2 2025, and 111.89% in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | 450.31% |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | 51.73% |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | -107.40% |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | -50.43% |
| 10 | IGC Pharma | 28.11 Mn | 27.85 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -110.45% |
| Jun 30, 2025 | -105.08% |
| Mar 31, 2025 | -111.89% |
| Dec 31, 2024 | -16.08% |
| Sep 30, 2024 | -29.38% |
| Jun 30, 2024 | -38.50% |
| Mar 31, 2024 | -33.13% |
| Dec 31, 2023 | -21.03% |
| Sep 30, 2023 | -12.82% |
| Jun 30, 2023 | -12.52% |
| Mar 31, 2023 | -14.66% |
| Dec 31, 2022 | -9.13% |
| Sep 30, 2022 | -8.77% |
| Jun 30, 2022 | -15.78% |
| Mar 31, 2022 | -11.84% |
| Dec 31, 2021 | -15.48% |
| Sep 30, 2021 | -14.89% |
| Jun 30, 2021 | -6.39% |
| Mar 31, 2021 | -6.69% |
| Dec 31, 2020 | -13.06% |